Spironolactone Therapy in Chronic Stable Right HF Trial
common.study.values.description
“Spironolactone Therapy in Chronic Stable Right HF Trial”
The purpose of this study is to evaluate the safety, tolerability and mechanistic effects of spironolactone, an aldosterone receptor antagonist, on sympathetic nervous system activity and right heart function and remodeling in patients with chronic right heart failure.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Spironolactone
Spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated for a total duration of 12 weeks.
Drug - Placebo
Placebo daily for a total of duration of 12 weeks
Radiation - PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82
At baseline and 12 weeks, all participants will undergo rest perfusion PET imaging according to standard protocols with either 82-Rb or N-13 NH3, followed by C-11 HED PET.
Diagnostic Test - Cardiac MRI (Gadolinium enhanced)
At baseline and 12 weeks all participants will undergo cMR to assess RV function and structure. We will acquire precontrast T2 and native T1 maps, and post gadolinium T1 maps.
participant.views.study.view.additional
participant.views.study.view.scientific-title
Spironolactone Therapy in Chronic Stable Right HF Trial
common.study.values.clinical-trial-id
NCT03344159
participant.views.study.view.id
7axDna
